Choroidal neovascularization (CNV) is the main cause of severe vision loss in patients with age-related macular degeneration (AMD) (1) . Inflammation is critically involved in the formation of CNV lesions (2, 3) and may contribute to the pathogenesis of AMD (2, 3) . For example, inflammatory cells are found in surgically excised CNV lesions from AMD patients (4 -7) and in autopsied eyes with CNV (8 -10). In particular, macrophages have been implicated in the pathogenesis of AMD due to their spatiotemporal distribution in the proximity of the CNV lesions in experimental models and humans (5, 6, 8, (11) (12) (13) (14) (15) .
Macrophages are a source of proangiogenic and inflammatory cytokines, such as vascular endothelial growth factor (VEGF) (12) and tumor necrosis factor (TNF) -␣ (16), both of which significantly contribute to the pathogenesis of CNV (17, 18) . Most of the macrophages found in the proximity of the laser-induced CNV lesions are derived from newly recruited peripheral blood monocytes and not resident macrophages (19) . Because macrophages play such a critical role in CNV formation, prevention of monocyte recruitment and infiltration into ocular tissues may ameliorate the development of CNV.
Vascular adhesion protein-1 (VAP-1) is an endothelial adhesion molecule involved in leukocyte recruitment (20, 21) . VAP-1 is a homodimeric sialylated glycoprotein expressed on the endothelium of human tissues such as skin, brain, lung, liver, and heart under both normal and inflamed conditions (22) (23) (24) (25) . We recently reported the localization of VAP-1 on the endothelium of the retinal vessels and the critical role of this molecule in the recruitment of leukocytes to the eye under inflammatory conditions (26) . Inhibition of VAP-1 function with a monoclonal antibody (mAb) suppresses recruitment of cells from the monocyte/ macrophage lineage (27) , suggesting an important role for VAP-1 in macrophage transmigration under pathological conditions. Because macrophages play a central role in CNV formation, we hypothesized that VAP-1 may regulate macrophage recruitment into ocular tissues under normal and pathological conditions and that its blockade may attenuate CNV formation.
In this study, we investigate the expression and distribution of VAP-1 in the choroidal tissues of normal and laser-injured animals. Furthermore, we examine the role of VAP-1 in CNV formation using a novel and specific inhibitor.
MATERIALS AND METHODS

Experimental animals
For reverse-transcription polymerase chain reaction (RT-PCR) detection and immunofluorescence staining of VAP-1 in the choroid, nonpigmented Lewis rats (8 -10 wk old, Charles River Laboratories, Inc., Wilmington, MA, USA) were used, whereas laser injury was conducted in pigmented Brown-Norway rats (10 -12 wk old, Charles River Laboratories, Inc.) to generate CNV. Rats were housed in plastic cages in a climate-controlled animal facility and were fed laboratory chow and water ad libitum. All animal experiments were conducted in accordance with the Association for Research in Vision and Ophthalmology Statement for the Use of Animals in Ophthalmic and Vision Research.
RNA extraction and RT-PCR
Lewis rats were euthanized by an overdose of anesthesia and perfused with PBS [500 ml/kg body weight (BW)]. Eyes were immediately enucleated, and the retinal pigment epithelium (RPE) -choroid complex was obtained from the rat eyes and homogenized in extraction reagent (TRIzol Reagent; Invitrogen, Carlsbad, CA, USA). As a control, the retinal tissues were separately obtained and processed. Total RNA was prepared according to the manufacturer's protocol, and equal amounts (1 g) of total RNA were reverse-transcribed with a FirstStrand cDNA synthesis kit (GE Healthcare, Buckinghamshire, UK) at 37°C for 1 h in a 15 l reaction volume. PCR was performed using Platinum PCR SuperMix (Invitrogen) with a thermal controller (GeneAmp PCR System 9700; Applied Biosystems, Foster City, CA, USA). The thermal cycle was 1 min at 94°C, 1 min at 55°C, and 1 min at 72°C, followed by 5 min at 72°C. The reaction was performed for 35 cycles for amplification of VAP-1 and 30 cycles for glyceraldehyde-3-phosphate dehydrogenase (GAPDH) with previously designed primers. The nucleotide sequences of the PCR primers were 5Ј-GAC CCT CGG ACA ACT GTG TCT T-3Ј (forward) and 5Ј-GCG TTT GTA GAA GCA ACA GTG A-3Ј (reverse) for VAP-1 (28) and 5Ј-TGG CAC AGT CAA GGC TGA GA-3Ј (forward) and 5Ј-CTT CTG AGT GGC AGT GAT GG-3Ј (reverse) for glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (29) . PCR products were analyzed by electrophoresis in a 1.5% agarose gel and stained with ethidium bromide (0.2 g/ml). The expected sizes of the amplified cDNA fragments of VAP-1 and GAPDH were 341 and 387 bp, respectively. Band densities were quantified using NIH Image 1.41 software (http://rsb.info.nih.gov/nih-image; developed by Wayne Rasband, National Institutes of Health, Bethesda, MD, USA). The expression level of VAP-1 mRNA was normalized by that of GAPDH.
CNV induction
Brown-Norway rats were anesthetized with 0.2-0.3 ml of a 50:50 mixture of 100 mg/ml ketamine and 20 mg/ml xylazine. Pupils were dilated with 5.0% phenylephrine and 0.8% tropicamide. CNV was induced with a 532 nm laser (Oculight GLx, Iridex, Mountain View, CA, USA). Six laser spots (150 mW, 100 m, 100 ms) were placed in each eye using a slit-lamp delivery system and a cover glass as a contact lens.
Production of a bubble at the time of laser confirmed the rupture of the Bruch's membrane.
Immunohistochemistry
Seven days after laser injury paraffin sections of the choroidalscleral complex and optimal cutting temperature (OCT) compound-embedded sections of the rat eyes were prepared. The sections were incubated with blocking solution (Invitrogen) and then reacted with either mouse monoclonal antibody against rat VAP-1 (1:200; BD Biosciences, Franklin Lakes, NJ, USA) or rabbit polyclonal antibody against rat VAP-1 (1:200; Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA). For the OCT-embedded sections, biotinylatedisolectin B4 (1:100; Sigma, St. Louis, MO, USA) was also used to visualize the structure of the vessels in the CNV lesions. Thereafter, the sections were incubated for 30 min at room temperature with secondary antibodies (Alexa Fluor ® 546; Molecular Probes, Eugene, OR, USA) or fluorescein isothiocyanate (FITC) -conjugated streptavidin (Jackson ImmunoResearch Laboratories, Inc., West Grove, PA, USA) and mounted with Vectashield mounting media with 4Ј,6-diamino-2-phenylindole (DAPI) (Vector Laboratories, Burlingame, CA, USA). Photomicrographs were taken with a digital high-sensitivity camera (ORCA-ER C4742-95; Hamamatsu Photonics, Hamamatsu, Japan) through an upright fluorescent microscope (DM RXA; Leica, Solms, Germany). As a negative control, the primary antibodies were replaced with nonimmune mouse IgG (Dako North America, Inc., Carpinteria, CA, USA).
VAP-1 inhibition
To block VAP-1, we used the specific VAP-1 inhibitor U-V002, developed and provided by R-tech Ueno, Ltd., Tokyo, Japan (26) . U-V002 has an IC 50 of 0.007 M against human and 0.008 M against rat semicarbazide-sensitive amine oxidase (SSAO), whereas its IC 50 against the functionally related monoamine oxidase (MAO) -A and MAO-B is Ͼ10 M (26). SSAO inhibitors are subdivided into the main groups of hydrazine derivatives, arylalkylamines, propenyl-and propargylamines, oxazolidinones, and haloalkylamines (30) . U-V002 is a new small molecule and a derivative of 1,3-thiazole. After laser injury, the inhibitor (0.3 mg/kg BW) was administered to the animals by daily i.p. injection. Control animals received the same regimen of the vehicle solution (R-tech Ueno, Ltd).
Fluorescein angiography
Seven days after laser injury, vascular leakage from the CNV lesions was assessed using fluorescein angiography (FA), as described previously (31) . Briefly, FA was performed in anesthetized animals from VAP-1 inhibitor-or vehicle-treated groups, using a digital fundus camera (TRC 50 IA; Topcon, Paramus, NJ, USA). Fluorescein injections were performed intraperitoneally (0.2 ml of 2% fluorescein; Akorn, Decatur, IL, USA). FA images were evaluated by two masked retina specialists, as described previously (31) . Briefly, the grading criteria were as follows. Grade-0 lesions had no hyperfluorescence. Grade-I lesions exhibited hyperfluorescence without leakage. Grade-IIA lesions exhibited hyperfluorescence in the early or midtransit images and late leakage. Grade-IIB lesions showed bright hyperfluorescence in the transit images and late leakage beyond the treated areas. The Grade-IIB lesions were defined as clinically significant, as described previously (32) .
Choroidal flatmount preparation
One or 2 wk after laser injury and treatment with VAP-1 inhibitor or vehicle, the size of CNV lesions was quantified using choroidal flat mounts (33) . Briefly, rats were anesthetized and perfused through the left ventricle with 20 ml PBS followed by 20 ml of 5 mg/ml fluorescein-labeled dextran (FITC-dextran; MWϭ2ϫ10 6 , Sigma) in 1% gelatin. The eyes were enucleated and fixed in 4% paraformaldehyde for 3 h. The anterior segment and retina were removed from the eyecup. About 4 to 6 relaxing radial incisions were made, and the remaining RPE-choroidal-scleral complex was flatmounted with Vectashield Mounting Medium (Vector Laboratories) and coverslipped. Pictures of the choroidal flat mounts were taken, and Openlab software (Improvision, Boston, MA, USA) was used to measure the hyperfluorescent areas corresponding to the CNV lesions. The average size of the CNV lesions was then determined and used for the evaluation.
Quantification of the macrophage infiltration
One, 3, and 7 days after laser injury and treatment with either VAP-1 inhibitor or vehicle solution, animals were perfused with 200 ml of PBS/kg BW under deep anesthesia. Subsequently, eyes were enucleated and fixed overnight with 4% PFA, and 10 m frozen sections of the posterior segment, including the central portion of CNV lesions (6 lesions per eye), were prepared and preblocked (PBS containing 10% goat serum, 0.5% gelatin, 3% BSA, and 0.2% Tween 20). The sections were incubated with mouse monoclonal antibody for ED1, rat homologue of human CD68 (1:100; BD Pharmingen, San Diego, CA, USA), and subsequently with the secondary antibody (goat anti-mouse IgG conjugated to Alexa Fluor 488; Molecular Probes). Sections were mounted with Vectashield mounting media (Vector Laboratories). Photographs of the CNV lesions were taken, and the number of ED-1-positive cells was counted. To obtain a quantitative index of macrophage numbers in the CNV lesions, an optical density plot of the selected area was generated by a histogram graphing tool in the Photoshop image-analysis software (version 6.0; Adobe Systems, Mountain View, CA), as described previously (14, 34, 35) . Image analysis was performed in a masked fashion.
Enzyme-linked immunosorbent assay for TNF-␣, monocyte chemotactic protein (MCP) -1, and intercellular adhesion molecule (ICAM) -1
The RPE-choroid complex was microsurgically isolated from eyes 3 days after photocoagulation. The complex was then placed in 300 l of lysis buffer supplemented with protease inhibitors and sonicated. The lysate was centrifuged at 15,000 rpm for 15 min at 4°C, and the levels of TNF-␣, MCP-1, and ICAM-1 were determined with rat TNF-␣ (BD Bioscience), MCP-1 (BD Bioscience), and ICAM-1 (R&D Systems, Minneapolis, MN, USA) enzyme-linked immunosorbent assay (ELISA) kits according to the manufacturers' protocols. Total protein concentration was determined using a Bio-Rad Protein Assay Kit (Bio-Rad Laboratories, Hercules, CA, USA) and dilutions of bovine serum albumin (Bio-Rad Laboratories) as standards.
Statistical analysis
All results are expressed as mean Ϯ se with n as indicated. Student's t test was used for statistical comparison between the groups. The results of the FA gradings were compared using the 2 test. Differences between the means were considered statistically significant at values of P Ͻ 0.05.
RESULTS
VAP-1 expression in the choroid and CNV
To determine whether VAP-1 is expressed in the choroid, we examined the level of its mRNA expression by RT-PCR and its protein expression by immunofluorescence staining. Because choroidal tissues and RPE cells usually contain melanin (36) , which binds to thermostable DNA polymerase and interferes with the PCR amplification (37), we used albino rats that lack melanin. In line with our previous study (26) , VAP-1 mRNA was detectable in the retina under normal conditions (Fig. 1) . Furthermore, RT-PCR revealed constitutive VAP-1 mRNA expression in the RPE-choroid complex under normal conditions (Fig. 1A) . Semiquantitative analysis of the band intensity showed a 2.8-fold higher expression of VAP-1 mRNA in the RPE-choroid complex compared with that in the retinal tissues (nϭ4 in each group, PϽ0.01; Fig. 1B ). In addition, immunofluorescence staining of sections from the eyes of normal animals showed the expression of VAP-1 protein in the choroid (Fig. 2) and that VAP-1 was exclusively localized in the vessels (Fig. 2) . 
Role of VAP-1 in CNV formation
To examine whether VAP-1 contributes to CNV formation, we photocoagulated the fundus of Brown-Norway rats with and without VAP-1 blockade and quantified the size of the CNV in flat mounts of the RPE-choroid complex. We examined the VAP-1 localization in CNV by immunofluorescence staining. The staining for VAP-1 protein was colocalized with isolectin B4 staining in arborizing CNV (Fig. 3) , suggesting that vascular endothelial cells in the CNV lesion also express VAP-1. Seven days after laser injury, the animals treated with VAP-1 inhibitor showed a significant decrease in CNV size (14,536Ϯ2175 m 2 ; nϭ7), compared with vehicletreated animals (25,026Ϯ1586 m 2 , nϭ9, PϽ0.01) (Fig. 4B) . However, 14 days after laser injury, the CNV size in the VAP-1 inhibitor-treated animals was not significantly different compared with the vehicletreated controls (23,992Ϯ1437 vs. 26681Ϯ3572 m 2 , nϭ10 and 9 eyes, respectively; Pϭ0.5).
Fluorescent angiography showed that the incidence of the clinically significant CNV lesions, graded as IIB, was significantly decreased in VAP-1 inhibitor-treated animals (41.8%, nϭ12) in comparison with vehicletreated animals 7 days post-injury (64.5%, nϭ11; PϽ0.05) (Fig. 5) .
Effect of VAP-1 blockade on macrophage infiltration
To investigate whether VAP-1 inhibition affects macrophage infiltration into the CNV lesion, we performed immunostaining for ED-1, a macrophage-specific marker, and quantified the number of ED-1 positive cells in the CNV lesions of animals with or without VAP-1 inhibition. Consistent with our previous report (33), we found that macrophages were recruited to the CNV lesion with a peak 3 days after laser injury (Fig. 6) . In comparison, the number of accumulated macrophages 3 days after laser injury was significantly reduced by 41% with the blockade of VAP-1 (nϭ4, PϽ0.05; Fig. 6 ).
Reduction of inflammatory molecules by VAP-1 blockade
To investigate the mechanisms by which VAP-1 blockade suppresses CNV formation, we measured by ELISA the levels of the inflammation-associated molecules TNF-␣, MCP-1, and ICAM-1 in the RPE-choroid complex with or without CNV lesions 3 days after laser injury. Protein levels of TNF-␣ (282Ϯ18 pg/mg), MCP-1 (496Ϯ38 pg/mg) and ICAM-1 (50Ϯ4 ng/mg) in the RPE-choroid complex of normal rats were significantly increased in the rats with CNV (TNF-␣, 395Ϯ17 pg/mg, PϽ0.01; MCP-1, 797Ϯ53 pg/mg, PϽ0.01; ICAM-1, 66Ϯ3 ng/mg, PϽ0.01, respectively) 3 days after laser injury (Fig. 7) . The protein levels of TNF-␣, MCP-1, and ICAM-1 were significantly reduced in the RPE-choroid complex of the laser-treated animals that received the inhibitor compared with the vehicle controls (TNF-␣, 407Ϯ17 vs. 360Ϯ12 pg/mg, PϽ0.05; MCP-1, 969Ϯ93 vs. 662Ϯ52 pg/mg, PϽ0.01; ICAM-1, 71Ϯ4 vs. 57Ϯ2 ng/mg, PϽ0.01, respectively). No statistical difference was found in the protein levels between vehicle-treated and vehicle-untreated CNV animals (TNF-␣, Pϭ0.6; MCP-1, Pϭ0.1; ICAM-1, Pϭ0.3, respectively) .
DISCUSSION
Recently, we showed a critical role for VAP-1 during acute ocular inflammation (26) . However, whether VAP-1 contributes to the pathogenesis of AMD is unknown. Because inflammatory processes are involved in the development of AMD, we investigated the role of VAP-1 in the formation of CNV, an integral component of AMD. This work shows a novel link between VAP-1 and angiogenesis.
We found constitutive expression of VAP-1 in the choroid and the retina, suggesting a role for VAP-1 in leukocyte extravasation in both vascular beds. The higher expression of VAP-1 in the choroid compared to the retina may in part be due to the higher vascular density of the choroid compared to the retina. Our histological findings led us to hypothesize that VAP-1 may be involved in CNV by contributing to the inflammatory leukocyte accumulation. Indeed, VAP-1 blockade significantly reduces the CNV size 7 days after laser injury and macrophage accumulation at the peak of CNV growth, 3 days after laser injury. This finding suggests that the reduction of the CNV formation by VAP-1 blockade may primarily be due to suppression of macrophage recruitment (13) (14) (15) . However, 14 days after laser injury, VAP-1 inhibition did not reduce CNV size, suggesting the existence of other VAP-1 independent angiogenic mechanisms that may compensate for the antiangiogenic effect of VAP-1 inhibition 7 days after laser injury. Indeed, emerging evidence suggests that inhibition of a single angiogenic factor may lead to up-regulation of other factors with functional overlap (38) . A variety of cytokines, chemokines, and endothelial adhesion molecules play important roles in the pathogenesis of CNV (16, 39, 40) . In the current study, we investigated the impact of VAP-1 blockade on the production levels of selected members of these inflammation-associated molecules. VAP-1 blockade significantly decreases the protein levels of the inflammatory cytokine TNF-␣ in the RPE-choroid complexes with CNV. Because macrophages in CNV lesions are a source of TNF-␣ (16), it is possible that the inhibition of macrophage infiltration by VAP-1 blockade may underlie the decreased level of TNF-␣ in the CNV lesions (17, 18) . TNF-␣ inhibition reduces experimentally induced CNV (18) . Furthermore, anti-TNF-␣ therapy in patients with inflammatory arthritis, who also had AMD, resulted in partial CNV regression and visual acuity improvement (17) . Our FA data show fewer lesions with clinically relevant leakage after VAP-1 blockade, suggesting that TNF-␣ reduction through VAP-1 blockade could be an alternate strategy for treatment of AMD.
In addition to TNF-␣, VAP-1 blockade also significantly reduces the expression of the potent macrophage-recruiting chemokine MCP-1 in the RPE-choroid complex after laser injury. In vitro, TNF-␣ stimulates the expression of MCP-1 in RPE cells (41) (42) (43) . Our data support a model in which reduced levels of MCP-1 lead to decreased macrophage infiltration. This would cause further reduction of TNF-␣ release, which in turn would lead to a diminished secretion of MCP-1 in RPE cells (Fig. 8) . VAP-1 blockade may thus interrupt this perpetual cascade of inflammatory events that exacerbate CNV formation at the stage of macrophage transmigration.
We also found that VAP-1 blockade significantly reduces the expression of ICAM-1 in choroidal tissues with CNV. ICAM-1, an endothelial adhesion molecule that regulates leukocyte recruitment, is up-regulated in the RPE-choroid complex during CNV formation (40, 44) . Mice deficient for ICAM-1 or its counter receptor, CD18, develop significantly smaller CNV lesions compared with wild-type (45), suggesting a key role for ICAM-1 in CNV formation. The reduction of ICAM-1 expression after VAP-1 blockade in laser-injured eyes may result in lower macrophage infiltration and smaller CNV lesions. Overall, VAP-1 blockade appears to effectively suppress key molecular and cellular components in a cascade leading to CNV formation (Fig. 8) . This may be achieved through inhibition of macrophage infiltration and through reduction of the levels of inflammatory cytokines, chemokines, and adhesion molecules.
In summary, we show that VAP-1 blockade with a novel and specific inhibitor effectively suppresses CNV 
